Received Mar 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 3939H2S | — |
Extra dose/ third dose administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 73-year-old male patient who received Herpes zoster (Shingrix) (batch number 3939H2S, expiry date 10-MAR-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 19-FEB-2020) and Shingrix (received 2nd dose on 06-AUG-2020). On 18-FEB-2025, the patient received the 3rd dose of Shingrix. On 18-FEB-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Extra dose/ third dose administered). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 04-MAR-2025 The Vaccine Administration Facility is the same as Primary Reporter The Practice Director called to enquire if there was any issue with a patient that had the complete schedule for Shingrix vaccine, and received an extra dose (third dose) a few weeks ago. The patient had received the 3rd dose of Shingrix, which had led to extra dose administered.